Chronic Anal Fissure with Stigmata of Chronicity — What to Do After First-Line Topical Therapy Fails

Clinical scenario

This protocol addresses patients with a chronic anal fissure that displays one or more stigmata of chronicity — such as a hypertrophied anal papilla, a sentinel tag, or exposed internal anal sphincter muscle at the base of the fissure — and who do not have baseline fecal incontinence. Fissures of longer duration are more likely to develop these features.

Previous treatment — failure condition that triggers this protocol

First-line topical pharmacologic therapy — either topical nitrates (glyceryl trinitrate) or topical calcium channel blockers (diltiazem or nifedipine) — did not achieve healing of the chronic anal fissure. This protocol represents the structured next step after that failure.

Next-step approach (partial overview)

The second-line approach centres on botulinum toxin injection targeting the internal anal sphincter. An additional topical agent may be considered in combination. The complete protocol details the clinical decision criteria, approach specifics, and management considerations.

Treatment goal: healing of the anal fissure and at least a 50% reduction in pain score at 3 months.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1097/DCR.0000000000002664

Fissures of a longer duration will often manifest 1 or more stigmata of chronicity, including a hypertrophied anal papilla at the proximal aspect of the fissure, a sentinel tag at the distal aspect of the fissure, and/or exposed internal anal sphincter muscle within the base of the fissure.

Botulinum toxin has similar results compared with topical therapies as first-line therapy for chronic anal fissures and modest improvement in healing rates as second-line therapy following failed treatment with topical therapies.

The use of topical nitroglycerin combined with botulinum toxin has been suggested to improve healing and symptoms in patients with chronic anal fissure.

A double-blind randomized trial comparing topical 2% DTZ with 20 units of botulinum toxin (using placebo injections and topical preparations, respectively) demonstrated that both treatment arms were associated with a 43% healing rate after 3 months, and similar rates of patients reporting at least a 50% reduction in pain score (82% vs 78%; p = 0.142).

View source ↗